ArticleBreast cancer research : BCR2025
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.
Marcin Kubeczko et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.